A mist inhaler used to deliver Spiriva to patients with chronic obstructive pulmonary disease (COPD) may be linked to an …

Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …
Global life sciences executive search and interim management firm RSA has made a series of new appointments across its business. …
The government will make major amendments to its controversial Health and Social Care Bill, including minimising the scope of regulator …
GlaxoSmithKline is increasing its footprint in China, shelling out £24 million ($39 million) to buy the remaining stake in a …
GSK is to team up with UK company Arecor to develop advanced formulations of GSK’s vaccines. Cambridge-based Arecor has developed …

This week the ABPI released guidance on managing adverse events from social media and the internet in a document that …

The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month. …

Merck & Co is to develop its own version of Pfizer’s ageing arthritis drug Enbrel with a South Korean manufacturer. …
The role of GPs and competition in the government’s Health Bill should be greatly diluted and its reform programme substantially …
Dr Stuart Best has joined Xceleron as senior director operations, moving to the company from Merck in Scotland where he …
The FDA has asked US drugmakers to give advance warning of production problems which could lead to shortages in available …
Baxter loses first heparin lawsuit, Pfizer plans a branded generics push in China, plus there’s updates from GSK, Hovione and …

Pfizer has expanded its options for its main European research site, earmarked for closure in Feburary, and is now marketing …
The FDA has approved a major overhaul of labelling for a range of Merck & Co products, paving the way …

The number of people in Europe who go online to look for health information has more than doubled over the …
In recent times new drug development has shown a substantial decline in the number of approved drugs for human use. …
Gilead Sciences is being investigated by the US authorities over the manufacturing and distribution of some of its products, and …
Brand(x) is changing its name to ICC Lowe and will act as the London office for its expanding US parent …
Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …